论文部分内容阅读
近年来,对血小板生理和前列腺素代谢的研究取得了重大进展,从而在冠心病防治上出现了新的概念——抗血小板疗法。阿斯匹林(乙酰水杨酸Acetylsalicylic Acid,下简称ASA)是一种非固醇类抗炎药。自Weiss等(1967)提出口服ASA可能作为抗血栓制剂以来,对ASA类药物抑制血小板的作用进行了广泛研究和临床试验,探索其对冠心病的作用,迄今尚未有结论性意见。本文试图对ASA在冠心病中应用的研究概况,就某些问题作简要文献复习,以供参考。一、阿斯匹林的抗血小板作用在了解ASA抗血小板作用之前,先概略温习前列腺素(PG)前体——花生四烯
In recent years, great progress has been made in the study of platelet physiology and prostaglandin metabolism, so that a new concept of anti-platelet therapy has emerged in the prevention and treatment of coronary heart disease. Aspirin (Acetylsalicylic Acid, ASA for short) is a non-steroidal anti-inflammatory drug. Since Weiss et al. (1967) suggested that oral ASA may be used as an antithrombotic agent, extensive studies and clinical trials on the anti-thrombotic effect of ASA drugs have been conducted to explore their effects on coronary heart disease. Up to now, no conclusive remarks have been made. This article attempts to ASA in coronary heart disease in the application of research profiles, on some issues for a brief review of the literature for reference. First, the anti-platelet effect of aspirin In understanding the anti-platelet function of ASA before a brief review of prostaglandin (PG) precursor - arachidonic